Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Receivables (2020 - 2025)

Kymera Therapeutics (KYMR) has disclosed Receivables for 6 consecutive years, with $40.0 million as the latest value for Q2 2025.

  • On a quarterly basis, Receivables rose 2247.42% to $40.0 million in Q2 2025 year-over-year; TTM through Jun 2025 was $40.0 million, a 2247.42% increase, with the full-year FY2024 number at $900000.0, down 95.2% from a year prior.
  • Receivables was $40.0 million for Q2 2025 at Kymera Therapeutics, up from $900000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $40.0 million in Q2 2025 to a low of $900000.0 in Q4 2024.
  • A 5-year average of $8.6 million and a median of $1.9 million in 2021 define the central range for Receivables.
  • Peak YoY movement for Receivables: plummeted 95.2% in 2024, then skyrocketed 2247.42% in 2025.
  • Kymera Therapeutics' Receivables stood at $1.8 million in 2021, then soared by 42.37% to $2.5 million in 2022, then surged by 650.48% to $18.8 million in 2023, then tumbled by 95.2% to $900000.0 in 2024, then surged by 4344.44% to $40.0 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Receivables are $40.0 million (Q2 2025), $900000.0 (Q4 2024), and $1.3 million (Q3 2024).